Taken together, KIR–HLA ligand mismatch between the licensed NK cells, particularly of strongly inhibitory KIR2DL1, and GBM cells’ cognate HLA ligands at the genomic level contributed to susceptibility for NK cell-mediated lysis. Here, KIR2DL1 is linked to glioblastoma.